Sufotidine 600 mg bd virtually eliminates 24 hour intragastric acidity in duodenal ulcer subjects.

Abstract

In a double blind study, 24 hour intragastric acidity and 24 hour plasma gastrin concentrations were measured simultaneously in seven duodenal ulcer subjects on the fifth day of receiving either sufotidine 600 mg bd or placebo. Compared with placebo, during treatment with sufotidine 600 mg bd the median integrated 24 hour intragastric acidity was decreased by 95% (range 74% to 99%) from 1000 to 51 mmol/h/l, whilst the median integrated 24 hour plasma gastrin concentration increased from 416 to 927 pmol/h/l.

• Authors: J T Smith, R E Pounder
• Journal: Gut (Gut) Vol. 31 Issue 3 Pg. 291-3 (Mar 1990) ISSN: 0017-5749 [Print] England
• PMID: 1969833 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Gastrins
• Histamine H2 Antagonists
• Piperidines
• Triazoles
• sufotidine

Topics

• Adult
• Circadian Rhythm
• Double-Blind Method
• Duodenal Ulcer (drug therapy, metabolism)
• Gastric Acid (metabolism)
• Gastrins (blood)
• Histamine H2 Antagonists (administration & dosage, therapeutic use)
• Humans
• Male
• Middle Aged
• Piperidines (administration & dosage, therapeutic use)
• Triazoles (administration & dosage, therapeutic use)